Clinical Trial Update: Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial evaluating long-term safety and efficacy of HB0034 in generalized pustular psoriasis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis

Drugs mentioned

• HB0034

Snippet

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Conditions: Generalized Pustular Psoriasis | Phase 2, Phase 3 | Status: RECRUITING